Hydrocortisone (Topical)
Hydrocortisone Topical — Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Corticosteroid-responsive dermatoses (general) | Adults and children ≥2 years | Monotherapy or adjunctive | FDA Approved |
| Atopic dermatitis (mild) | Adults and children ≥2 years; butyrate 0.1% approved ≥3 months | Monotherapy | FDA Approved |
| Contact dermatitis | Adults and children ≥2 years | Monotherapy | FDA Approved |
| Seborrheic dermatitis | Adults and children ≥2 years | Monotherapy | FDA Approved |
| Psoriasis (mild, limited areas) | Adults | Monotherapy or adjunctive | FDA Approved |
| Anorectal pruritus / Hemorrhoids (rectal formulations) | Adults | Monotherapy | FDA Approved |
Topical hydrocortisone is a first-line agent for mild inflammatory dermatoses, particularly in anatomic areas where skin is thin and vulnerable to atrophy, such as the face, axillae, groin, and intertriginous folds. As the lowest-potency topical corticosteroid (US Class VII), it is the preferred steroid for sensitive skin sites and for pediatric patients. Hydrocortisone base (0.5% and 1%) is available over-the-counter in many countries; the 2.5% concentration and ester formulations (butyrate, valerate, probutate) require a prescription and carry higher potency classifications.
Intertrigo (intertriginous dermatitis): Short-course hydrocortisone 1% cream for inflammatory component alongside antifungal therapy. Evidence quality: Moderate (consensus-based guidelines, expert opinion).
Phimosis (pediatric): Hydrocortisone 1–2.5% cream applied to the prepuce for 4–8 weeks as a conservative first-line alternative to circumcision. Evidence quality: Moderate (multiple small RCTs support topical corticosteroid efficacy as a class).
Insect bite reactions: Widely used OTC for symptomatic relief of localized pruritus and inflammation from insect stings and bites. Evidence quality: Low (empirical use, limited formal trials).
Dosing
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Mild eczema — body/trunk | 1–2.5% cream/ointment BID–QID | 1% cream BID | 2.5% QID | Apply thin film; taper to least frequency that controls symptoms Ointment preferred for dry/lichenified areas |
| Facial / intertriginous dermatitis | 0.5–1% cream BID | 0.5–1% cream daily–BID | 1% BID | Preferred steroid for face, axillae, groin due to low potency Limit to 2–4 weeks on facial skin |
| Contact dermatitis — localized mild | 1% cream TID–QID | 1% cream BID–TID | 2.5% QID | Apply to affected area only; assess at 2 weeks Switch to higher potency if no improvement in 7 days |
| Psoriasis — thin-skin sites (face, folds) | 1–2.5% cream BID | 1% cream daily–BID | 2.5% BID | For intertriginous psoriasis only; plaque psoriasis on trunk requires higher potency May use under occlusion for recalcitrant areas per FDA PI |
| Seborrheic dermatitis — scalp/face | 1% lotion/cream BID | 1% lotion/cream daily | 2.5% BID | Lotion preferred for scalp; combine with antifungal shampoo Cream for facial seborrheic dermatitis |
| Insect bites / minor skin irritation (OTC) | 0.5–1% cream TID–QID | As needed | 1% QID | Limit OTC use to 7 days without physician guidance For external use only; not for eyes, mouth, or genitals without Rx |
Pediatric Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Mild atopic dermatitis — children ≥2 y | 1% cream BID | 1% cream daily–BID | 1% BID | Apply smallest amount to smallest area; avoid tight-fitting diapers over treated area Children have higher BSA-to-weight ratio — increased systemic absorption risk |
| Mild atopic dermatitis — infants ≥3 months (butyrate 0.1%) | Butyrate 0.1% lotion BID | BID for up to 2 weeks | BID × 4 weeks max | Locoid lotion specifically approved ≥3 months for atopic dermatitis Reassess if no improvement in 2 weeks (FDA PI) |
| Diaper dermatitis (non-infectious) | 0.5–1% cream BID | BID × 3–7 days | 1% BID × 7 days | Do not apply under occlusive diapers or plastic pants Use barrier cream alongside; rule out candidal infection |
Hydrocortisone base 1% and 2.5% are Class VII (lowest potency). Hydrocortisone butyrate 0.1% (Locoid) is Class VI, hydrocortisone valerate 0.2% (Westcort) and hydrocortisone probutate 0.1% (Pandel) are Class V (medium potency). Ester modifications alter potency significantly — always check the specific salt form when prescribing or substituting.
Pharmacology
Mechanism of Action
Hydrocortisone is a naturally occurring glucocorticoid identical to endogenous cortisol. When applied topically, it diffuses across cell membranes and binds intracellular glucocorticoid receptors (GRs) in the cytoplasm. The activated receptor-ligand complex translocates to the nucleus, where it modulates transcription of target genes. The anti-inflammatory effects result from suppression of pro-inflammatory cytokines (including interleukin-1, interleukin-6, and tumour necrosis factor-alpha), inhibition of phospholipase A2 through induction of lipocortin, and consequent reduction of arachidonic acid release and downstream prostaglandin and leukotriene synthesis. Clinically, this manifests as reduced erythema, oedema, pruritus, and capillary dilation at the site of application. As a non-fluorinated, non-halogenated corticosteroid, hydrocortisone has the lowest anti-inflammatory potency among topical steroids, which translates to a favorable safety profile on sensitive skin sites.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Percutaneous: <2% through intact skin (forearm); up to 36% on scrotal skin; increased by occlusion, inflammation, or damaged barrier | Systemic effects are rare with intact-skin application; caution with occlusive dressings or use on inflamed/eroded skin where absorption rises markedly |
| Distribution | Vd ~34 L (if absorbed systemically); ~92% protein-bound to CBG and albumin | CBG binding becomes saturated above plasma cortisol ~550 nmol/L, causing nonlinear rise in free cortisol; clinically irrelevant for topical use at standard doses |
| Metabolism | Hepatic: 11β-HSD converts to inactive cortisone; further 5β-reduction and conjugation; CYP3A4 involved | Minimal first-pass concern for topical use; drug interactions via CYP3A4 are only clinically relevant with systemic absorption |
| Elimination | Renal (>90% as conjugated metabolites); t½ 1.5–2 h (plasma); <1% excreted unchanged | Short plasma half-life means rapid offset of any absorbed drug; biologic half-life (tissue effect) is 8–12 hours |
Side Effects
Adverse effects of topical hydrocortisone are predominantly local and are uncommon with short-term use of low-potency formulations. Frequency data below are derived from post-marketing surveillance of topical corticosteroids as a class and the FDA prescribing information; incidence rates are generally lower for hydrocortisone (Class VII) compared with higher-potency agents.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Application-site burning / stinging | ~66%* | Most frequently reported local reaction across all topical corticosteroids in post-marketing data (AAFP 2009 review); typically transient and mild with hydrocortisone base |
* The 66% figure is from a post-marketing review of all topical corticosteroid classes combined (AAFP 2009). Incidence is substantially lower with hydrocortisone base given its low potency.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Pruritus at application site | 1–5% | Paradoxical itch may occur; distinguish from allergic contact dermatitis to hydrocortisone or vehicle preservatives |
| Skin dryness / irritation | 1–5% | More common with cream/lotion vehicles containing alcohol; ointment formulation less drying |
| Folliculitis | 1–3% | Reported infrequently per FDA PI; more likely under occlusion or in hairy areas |
| Hypopigmentation | 1–3% | Usually reversible; more noticeable in darker skin tones; related to duration of use |
| Acneiform eruptions | 1–2% | Steroid acne occurs with prolonged application, especially on the face; discontinue if papulopustular lesions develop |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| HPA axis suppression | Rare | Weeks to months of continuous use, especially under occlusion | Morning cortisol or ACTH stimulation test; taper or discontinue; supplement with systemic steroids if adrenal crisis suspected |
| Skin atrophy / striae | ~15%* | After prolonged use (>4 weeks), particularly on thin-skin sites | Discontinue; striae are irreversible. Atrophy may partially recover over months after cessation |
| Perioral dermatitis | Uncommon | Weeks of facial application | Discontinue topical steroid (may temporarily worsen); treat with topical metronidazole or oral tetracycline if needed |
| Allergic contact dermatitis (to hydrocortisone or vehicle) | Rare (<1%) | Days to weeks after initiation | Patch testing to confirm; switch to a different structural group corticosteroid |
| Glaucoma / increased intraocular pressure | Very rare | With periocular application over weeks | Ophthalmology referral; discontinue periocular steroid; IOP monitoring |
| Cushing syndrome (iatrogenic) | Very rare | Prolonged extensive use or under occlusion | Gradual taper; endocrinology referral; do not withdraw abruptly |
* Striae/atrophy 15% figure from post-marketing review across all topical corticosteroid classes (AAFP 2009). Incidence is considerably lower for hydrocortisone base when used appropriately for short durations.
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Local irritation or burning | <2% | Most common reason for switching; usually to a different vehicle rather than stopping treatment entirely |
| Treatment failure (inadequate potency) | Variable | Not a side effect but the most frequent reason patients stop hydrocortisone; step up to mid-potency agent if no improvement in 2 weeks |
| Allergic contact dermatitis | <1% | Requires patch testing and permanent avoidance of hydrocortisone-type (Group A) corticosteroids |
Skin atrophy is the most clinically relevant local adverse effect of topical corticosteroids. For hydrocortisone base, the risk is low when used for ≤4 weeks on intact skin. To minimize risk: use the lowest effective strength, apply the thinnest layer possible, avoid occluded or intertriginous sites beyond 2 weeks, and consider “steroid holidays” (e.g., weekends off) during maintenance therapy. If early atrophy signs appear (skin thinning, telangiectasia, easy bruising), discontinue immediately. Atrophy typically reverses over 2–4 months after stopping, though striae are permanent.
Drug Interactions
Topical hydrocortisone has minimal systemic absorption (<2% through intact skin), which makes clinically significant drug-drug interactions rare. Most interactions listed below are pharmacodynamically mediated or become relevant only with prolonged use over large body surface areas, under occlusion, or on damaged skin where absorption increases substantially. Hydrocortisone is metabolized hepatically via CYP3A4 and 11β-HSD pathways.
Monitoring
-
Skin Integrity
Each visit
Routine Inspect application sites for signs of atrophy (thin, translucent skin), telangiectasia, striae, purpura, or secondary infection. Assess treatment response and consider stepping down or discontinuing if the dermatosis has cleared. -
Treatment Duration
2–4 week review
Routine Reassess at 2 weeks (sooner for facial use). If no improvement, reconsider diagnosis or step up potency. Prolonged continuous use beyond 4 weeks on the same site warrants clinician re-evaluation. -
Growth (Pediatric)
Regular intervals
Routine Children on prolonged topical corticosteroid therapy should have height and weight tracked routinely. Growth suppression is rare with low-potency agents but possible with extensive or chronic use. -
HPA Axis Function
If clinically indicated
Trigger-Based Morning serum cortisol or ACTH stimulation test if using high-dose topical hydrocortisone over large BSA, under occlusion, or for >4 weeks continuously. Look for signs of adrenal suppression: fatigue, hypotension, weight loss. -
Intraocular Pressure
If periocular use
Trigger-Based Refer for ophthalmologic evaluation if topical corticosteroid is applied near the eyes for >2 weeks. Cases of glaucoma have been reported with periorbital steroid use even with low-potency agents. -
Secondary Infection
Each visit
Trigger-Based If treated dermatosis worsens or new pustules, crusting, or satellite lesions appear, evaluate for bacterial or fungal superinfection. Discontinue occlusive dressings and initiate antimicrobial therapy.
Contraindications & Cautions
Absolute Contraindications
- Hypersensitivity to hydrocortisone, other corticosteroids, or any excipient in the formulation (lanolin, propylene glycol, preservatives).
- Untreated bacterial, viral (herpes simplex, varicella), or fungal skin infections at the proposed application site — corticosteroids suppress local immunity and will worsen active infection.
- Rosacea or perioral dermatitis — topical corticosteroids cause or exacerbate these conditions.
- Acne vulgaris — steroids worsen acne through follicular occlusion and immunosuppression.
Relative Contraindications (Specialist Input Recommended)
- Application to large body surface area (>20% BSA) or under occlusion — significantly increases percutaneous absorption and risk of systemic effects; requires documented risk-benefit assessment.
- Periocular application — risk of cataracts and glaucoma with prolonged use; ophthalmology consultation advised if >2 weeks.
- Pregnancy (extensive or prolonged use) — animal studies show teratogenicity with systemic exposure; limited localized use of low-potency hydrocortisone is generally considered acceptable, but extensive application should be discussed with obstetrics.
- Pre-existing skin atrophy or thin skin in elderly patients or on sites with prior steroid use — increased vulnerability to further thinning and striae.
Use with Caution
- Children — higher body surface area-to-weight ratio increases systemic absorption risk; use the lowest effective potency and duration.
- Diabetes mellitus — extensive topical steroid use may theoretically affect blood glucose; clinically unlikely with standard hydrocortisone dosing but worth awareness.
- Diaper area in infants — diapers and plastic pants create an occlusive environment; do not cover treated skin with tight-fitting diapers.
- Compromised skin barrier (burns, excoriation, dermatitis with erosion) — enhanced absorption through damaged stratum corneum.
Prolonged use of topical corticosteroids, particularly under occlusion, on large body surface areas, or on thin-skinned sites may suppress the hypothalamic-pituitary-adrenal axis, resulting in secondary adrenal insufficiency. Pediatric patients are especially susceptible due to greater percutaneous absorption relative to body weight. If HPA suppression is suspected, attempt to withdraw the drug or reduce application frequency, and evaluate adrenal function. Systemic corticosteroid supplementation may be necessary during physiologic stress.
Patient Counselling
Purpose of Therapy
Hydrocortisone cream, ointment, or lotion reduces inflammation, redness, and itch caused by various skin conditions. It works by calming the immune response in the skin. It is one of the mildest steroid creams available and is appropriate for use on sensitive areas such as the face and skin folds when directed by a clinician.
How to Apply
Wash and dry the affected area gently. Apply a thin film of hydrocortisone to the affected skin only — avoid spreading to surrounding healthy skin. Rub in gently until the cream or ointment is no longer visible. Wash hands thoroughly after application (unless hands are the treatment area). Do not bandage, wrap, or cover the treated area unless specifically instructed by your prescriber, as covering increases absorption and side effect risk.
Sources
- Hydrocortisone Cream USP 1% and 2.5% — FDA-approved Prescribing Information. Taro Pharmaceuticals. drugs.com/pro/hydrocortisone Primary FDA label for hydrocortisone cream base: indications, dosing, adverse reactions, and contraindications.
- LOCOID (hydrocortisone butyrate) Lotion 0.1% — FDA Prescribing Information (2023). accessdata.fda.gov FDA label for hydrocortisone butyrate lotion; includes age-specific approvals and HPA suppression data.
- PANDEL (hydrocortisone probutate) Cream 0.1% — FDA Prescribing Information (2017). accessdata.fda.gov FDA label for the probutate ester; covers adult-only indication and reproductive toxicity data.
- Ference JD, Last AR. Choosing Topical Corticosteroids. Am Fam Physician. 2009;79(2):135–140. aafp.org AAFP review of topical steroid potency classification, post-marketing safety data including local irritation and atrophy rates, and evidence-based selection.
- Stacey SK, McEleney M. Topical Corticosteroids: Choice and Application. Am Fam Physician. 2021;103(6):337–343. PMID: 33750316. Updated clinical guidance on topical corticosteroid selection, potency matching by body site, and duration limits.
- Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis (Section 2: Management and treatment). J Am Acad Dermatol. 2014;71(1):116–132. doi:10.1016/j.jaad.2014.03.023 AAD guideline recommending topical corticosteroids as first-line for atopic dermatitis, with potency selection guidance.
- Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54(1):1–15. doi:10.1016/j.jaad.2005.01.010 Comprehensive review of local and systemic adverse effects of topical corticosteroids, including atrophy, striae, and HPA suppression data.
- Abraham A, Roga G. Topical Steroid-Damaged Skin. Indian J Dermatol. 2014;59(5):456–459. doi:10.4103/0019-5154.139872 Review of systemic side effects of topical corticosteroids including HPA suppression, percutaneous absorption factors, and pediatric vulnerability.
- Topical Corticosteroids. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. ncbi.nlm.nih.gov/books/NBK532940 Comprehensive NCBI reference covering mechanism of action, potency classification (Class I–VII), and drug interaction profile for topical steroids.
- Samaras EG, Riviere JE, Ghafourian T. The effect of formulations and experimental conditions on in vitro human skin permeation: data from updated EDETOX database. Int J Pharm. 2012;434(1-2):280–291. doi:10.1016/j.ijpharm.2012.05.012 Percutaneous absorption data relevant to understanding variable bioavailability of topical hydrocortisone by body site and vehicle.
- Derendorf H, Möllmann H, Barth J, Möllmann C, Tunn S, Krieg M. Pharmacokinetics and oral bioavailability of hydrocortisone. J Clin Pharmacol. 1991;31(5):473–476. doi:10.1002/j.1552-4604.1991.tb01906.x Landmark PK study establishing hydrocortisone half-life (1.7 h), volume of distribution (34 L), and oral bioavailability (96%).
- Hydrocortisone, Topical. In: Drugs and Lactation Database (LactMed). Bethesda (MD): NICHD; 2024. ncbi.nlm.nih.gov/books/NBK501276 LactMed summary of topical hydrocortisone safety during breastfeeding; confirms low risk with standard use.
- Vestergaard C, Wollenberg A, Barbarot S, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. J Eur Acad Dermatol Venereol. 2019;33(9):1644–1659. doi:10.1111/jdv.15709 European consensus position on corticosteroid safety in pregnancy and lactation, supporting limited topical corticosteroid use.